课题基金 / 基金详情

Project 1: AMPK and Inflammation in Gout

Project 1: AMPK and Inflammation in Gout
项目 1:AMPK 与痛风炎症
批准号:
10263204
负责人:
Robert A. Terkeltaub
金额:
$28.29万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-20 至 2024-08-31
关键词:
5&apos-AMP-activated protein kinaseAcuteAddressAgeAllopurinolAncillary StudyAnti-Inflammatory AgentsArthritisAttenuatedBasic ScienceBiological AssayBiological MarkersBiosensorCardiovascular systemCaringClinical TrialsColchicineCrystallizationDepositionDiabetes MellitusEffectivenessEnzyme-Linked Immunosorbent AssayFlareFrequenciesGenderGilbert DiseaseGoutGouty ArthritisHealthHeart HypertrophyHomeostasisHospitalizationHypertensionHyperuricemiaImpairmentIn VitroInflammasomeInflammationInflammatoryInterleukin-1 betaInvestigationKidneyLeadLeukocytesLinkMaintenanceMaintenance TherapyMetabolicMetabolic syndromeMethotrexateModelingMonitorNon-Insulin-Dependent Diabetes MellitusNon-Steroidal Anti-Inflammatory AgentsObesityOutcomePatientsPeriodicityPhasePredispositionProphylactic treatmentProspective StudiesQuality of lifeReference StandardsRegulationRiskRoleSamplingSerumSeveritiesSiteSurrogate EndpointSurrogate MarkersTestingTherapeutic EffectTherapy trialTissuesTitrationsTransducersTranslatingTranslational ResearchTreatment EfficacyUrateUric AcidWorkactivity markeragedarthropathiesautoinflammatorycarbohydrate metabolismchemokineclinical decision-makingcomorbiditycomparative effectiveness studycost effectivefebuxostatin vivoinnovationkidney fibrosismacrophagemetabolomicsmultidisciplinarynon-alcoholicnonalcoholic steatohepatitisnovel markernutritionp65patient orientedperipheral bloodprecision medicinepredictive markerpreventprimary endpointprospectiveresponsestressortargeted treatmenttranscription factor

项目摘要

项目成果

Robert A. Terkeltaub的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 在痛风中,急性关节炎发作通常很严重,并损害生活质量。急性痛风发作提早增加,而且 坚持多年,在滴定和第一年的维持,否则成功的降尿酸治疗 (ULT)然而,症状性痛风在已确立的痛风中有不同的表现。此外,痛风并不是统一的 发展为无症状的高尿酸血症,尽管可检测到组织尿酸盐结晶沉积在~25%。血清尿酸 (SuA)水平有助于指导临床决策,例如,ULT到特定的SUA目标,或确定ULT疗效 (监测生物标志物)。SUA符合痛风替代生物标记物的标准,作为临床替代终点 审判。然而,SUA在评估痛风的炎症状态方面没有明确的作用。因此,有重大的 对更好的生物标记物的需求未得到满足不仅对于无症状高尿酸血症的痛风事件,而且对于 痛风患者会出现更频繁和更严重的红斑,从而推动痛风精准医学的发展。 (CORT主题),通过预测潜在毒性痛风发作的需要和持续时间,并监测其有效性 秋水仙碱或非甾体抗炎药的预防,特别是在开始和维持ULT之后。我们的科学前提直接 解决了这些需求,基于我们最近的发现,代谢能量生物传感器AMP激活 蛋白激酶(AMPK)控制痛风模型炎症的“开关”。值得注意的是,AMPK也是一种 秋水仙碱和甲氨蝶呤疗效的初级传感器。此外,我们还展示了引人注目的 痛风患者PBL AMPK活性降低与健康对照的初步研究。在这里,我们将 翻译基本发现,结构性AMPK活性显著限制尿酸盐的炎症潜能 体内的晶体,部分是通过钝化炎症主要调节因子NF-κB的激活和限制尿酸 巨噬细胞激活炎症小体/释放IL-1β。值得注意的是,AMPK活性既有 通过组织AMPK调节和反映营养、碳水化合物代谢和炎症应激源 已知的肥胖症、代谢综合征和2型糖尿病患者的活动量减少。值得注意的是,AMPK较低 运动促进常见的痛风共病(皮质醇主题),即高血压、慢性肾脏病的发病、进展 以及相关的肾纤维化、心肌肥大和非酒精性脂肪肝。来检验这一假设 低AMPK活性预示着更频繁和更严重的炎症性痛风性关节炎发作,我们将检测PBL 痛风的AMPK活性和特定的AMPK靶向代谢产物(通过代谢组学评估),健康对照, 和无症状的高尿酸血症。我们将在VA CSP594中对痛风受试者进行辅助研究 滴定的别嘌醇与非布司坦特的疗效比较,滴定到尿酸靶点,但有照明弹 以72周为主要终点。我们还将测试以下假设:在痛风患者中,低PBL AMPK活性是一种 对于炎性活动度大于中位数/年的患者,以及增加的NF-κB活性的标志物。 项目完成将把炎症的代谢调节转化为一种新的生物标记物和靶点 预防急性痛风发作。
英文摘要
PROJECT SUMMARY In gout, acute arthritis flares are often severe, and impair quality of life. Acute gout flares increase early, and persist for years, in the titration and first years of maintenance of otherwise successful urate-lowering therapy (ULT). Yet symptomatic gout manifests variably in established gout. Furthermore, gout does not uniformly develop in asymptomatic hyperuricemia, despite detectable tissue urate crystal deposits in ~25%. Serum urate (sUA) level helps guide clinical decision-making, eg, ULT to specific sUA target, or to identify ULT efficacy (monitoring biomarker). sUA fulfills criteria for gout surrogate biomarker, as a surrogate end point in clinical trials. However, sUA has no clear role in assessing the inflammatory state in gout. As such, there is major unmet need for better biomarkers not only for incident gout in asymptomatic hyperuricemia, but also for which gout patients will develop more frequent and severe flares, and thereby, to advance gout precision medicine (CORT theme), by predicting need and duration, and monitor effectiveness of potentially toxic gout flare colchicine or NSAID prophylaxis, particularly after starting and maintaining ULT. Our scientific premise directly addresses these needs, building on our recent discovery that the metabolic energy biosensor AMP activated Kinase (AMPK) controls "on and off switches" for model gouty inflammation. Remarkably, AMPK also is a primary transducer of therapeutic effects of colchicine and methotrexate. Moreover, we present striking Preliminary Studies for attenuated PBL AMPK activity in gout compared to healthy controls. Here, we will translate basic findings that constitutive AMPK activity markedly limits the inflammatory potential of urate crystals in vivo, partly by blunting activation of the inflammation master regulator NF-κB, and by limiting urate crystal NLRP3 inflammasome activation/IL-1β release by macrophages. Significantly, AMPK activity both regulates and reflects nutrition, carbohydrate metabolism, and inflammatory stressors, with tissue AMPK activity known to be diminished in obesity, metabolic syndrome, and type 2 diabetes. Significantly, low AMPK activity promotes common gout comorbid conditions (CORT theme), ie, hypertension, CKD onset, progression and associated renal fibrosis, cardiac hypertrophy, and nonalcoholic steatohepatosis. To test the hypothesis that low AMPK activity predicts more frequent and severe inflammatory gouty arthritis flares, we will assay PBL AMPK activity, and specific AMPK-targeted metabolites (assessed by metabolomics) in gout, healthy controls, and asymptomatic hyperuricemia. We will perform an ancillary study of gout subjects in the VA CSP594 comparative effectiveness study of titrated allopurinol vs. febuxostat ULT, titrated to urate target, but with flares at 72 weeks as the primary endpoint. We also will test the hypothesis that, in gout, low PBL AMPK activity is a marker for patients with greater than the median inflammatory flares/year, and for increased NF-κB activity. Project completion will translate metabolic regulation of inflammation to a novel biomarker and target for preventing acute gout flares.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intersections of matrix biology with inflammation in a new model of gout
  • 批准号:
    10579760
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    Robert A. Terkeltaub
  • 依托单位:
Novel Synovial Role in Pathogenesis of Gout
Rheumatic Diseases Research Training Grant
Rheumatic Diseases Research Training Grant
海外基金